share_log

IDEX Biometrics ASA - Contemplated Private Placement

IDEX Biometrics ASA - Contemplated Private Placement

IDEX Biometrics ASA-考慮的私募配售
GlobeNewswire ·  2023/11/15 23:31

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.

不得在澳大利亞、加拿大、日本或美國或任何其他非法發佈、出版或分發的司法管轄區直接或間接地發佈、出版或發行。本公告不構成此處所述任何證券的要約。

Oslo, 15 November 2023.

奧斯陸,2023年11月15日。

IDEX Biometrics ASA (the "Company"), a leading provider of advanced fingerprint identification and authentications solutions, has retained Arctic Securities AS as sole manager and bookrunner (the "Manager") to advise on and effect a private placement (the "Private Placement") of new shares in the Company (the "Offer Shares") to raise gross proceeds of up to NOK 35 million.

先進指紋識別和身份驗證解決方案的領先提供商IDEX Biometrics ASA(以下簡稱 “公司”)已聘請Arctic Securities ASA作爲唯一管理人和賬簿管理人(“管理人”),就公司新股(“私募配股”)提供建議和實施公司新股(“發行股”),籌集高達3,500萬挪威克朗的總收益。

The net proceeds from the Private Placement will be used to fund the Company's commercialization phase, necessary product development and market development expenses, working capital requirements, as well as other general corporate purposes.

私募的淨收益將用於爲公司的商業化階段、必要的產品開發和市場開發費用、營運資金需求以及其他一般公司用途提供資金。

In addition, the Company entered into a non-binding term sheet with a new institutional investor on 6 November 2023 to issue a senior convertible bond of up to NOK 100 million (as previously announced) (the "Convertible Bond").

此外,公司於2023年11月6日與一位新的機構投資者簽訂了不具約束力的條款表,發行高達1億挪威克朗的優先可轉換債券(如先前宣佈的那樣)(“可轉換債券”)。

The Company is also taking further actions to improve efficiencies as the Company progresses to a commercial phase and intends to reduce costs to enable a reduction to a quarterly opex level of approximately USD 4 million. With such cost reductions and the combined proceeds from the contemplated Private Placement and Convertible Bond, the Company expects to be fully funded through 2024.

隨着公司進入商業階段,公司還在採取進一步行動來提高效率,並打算降低成本,從而將季度運營支出降至約400萬美元的水平。有了這樣的成本降低以及計劃中的私募和可轉換債券的合併收益,該公司預計將在2024年之前獲得充足的資金。

Below is a summary of the main terms of the contemplated Convertible Bond:

以下是計劃中的可轉換債券的主要條款摘要:

  • IDEX Biometrics has entered into a non-binding term sheet with a new institutional investor to issue a senior convertible bond for up to 100 million NOK;
  • The conversion price for the bond is equal to 125% of the Reference Price (VWAP price of the shares for 5 trading days on the Oslo Stock Exchange prior to the date of signing) and the investors right to consent;
  • Interest rate is 6% p.a.;
  • The convertible bond will be issued at a price of 92% of the principal amount, and will be amortized over 3.5 years through equal instalments, including interest, every 2 months over the period.
  • The instalments may, in principle, be accelerated by 2 extra instalments each time and they may be deferred each time to a later date, however at the price on the original instalment date;
  • The Company, at its discretion, always has the option to make instalment payments in the form of cash or shares in the Company;
  • If the Company elects to make repayment of an instalment in shares, the shares shall be priced at 90% of the VWAP price for the shares for a period of 5 trading days on the Oslo Stock Exchange prior to the instalment date, or the VWAP the last trading day. In no event shall the share price exceed the conversion price.
  • The investor cannot trade more than 15% of the daily trading volume in the event the issue price of the shares is lower than the VWAP closing price on the trading day the day before, otherwise the trading limit is up to 20% of the daily trading volume;
  • Mechanisms adjusting the conversion price upon the occurrence of certain events (e.g. anti-dilution provisions, including a reset of the conversion price if there is a lower equity raise share price with the new conversion price equal to 100% of a lower placing price of such equity issue);
  • To approve the convertible bond, IDEX Biometrics will call for an extraordinary meeting on or about 8 December 2023 at 10:00 hours CET, held as an online meeting (the "EGM").
  • IDEX Biometrics已與一位新的機構投資者簽訂了不具約束力的條款表,以發行高達1億挪威克朗的優先可轉換債券;
  • 債券的轉換價格等於參考價格(簽署之日前奧斯陸證券交易所5個交易日的股票VWAP價格)和投資者同意權的125%;
  • 年利率爲6%;
  • 可轉換債券將以本金的92%的價格發行,並將在3.5年內通過等額分期償還,包括利息,在此期間每2個月攤還。
  • 原則上,每次分期付款可以加快兩期付款,並且每次可以推遲到以後的日期,但按最初的分期付款日期的價格計算;
  • 公司可自行決定隨時選擇以現金或公司股份的形式分期付款;
  • 如果公司選擇償還分期股票,則股票的定價應爲分期付款日之前在奧斯陸證券交易所的5個交易日或最後一個交易日的VWAP價格的90%。在任何情況下,股價均不得超過轉換價格。
  • 如果股票的發行價格低於前一天交易日的VWAP收盤價,則投資者的交易量不能超過每日交易量的15%,否則交易限額最高爲每日交易量的20%;
  • 在某些事件發生時調整轉換價格的機制(例如反稀釋條款,包括如果股權上漲股價較低,新的轉換價格等於此類股票發行較低配售價的100%,則重置轉換價格);
  • 爲了批准可轉換債券,IDEX Biometrics將在歐洲中部時間2023年12月8日左右上午10點召集一次特別會議,以在線會議(“臨時股東大會”)的形式舉行。

The Private Placement:

私募配售:

The subscription price per Offer Share in the Private Placement (the "Offer Price") and the number of Offer Shares to be issued in the Private Placement will be determined by the board of directors of the Company (the "Board") following an accelerated bookbuilding process. The bookbuilding period commences today at 16:30 CET and ends at 08:00 CET on 16 November 2023. The bookbuilding period may, at the discretion of the Company and the Manager, close earlier or later and may be cancelled at any time and, consequently, the Company may refrain from completing the Private Placement.

私募中每股發售股的認購價格(“發售價”)和在私募中發行的要約股份數量將由公司董事會(“董事會”)在加快賬簿建設流程後確定。簿記建設期從歐洲中部時間今天 16:30 開始,並於2023年11月16日歐洲中部時間 08:00 結束。根據公司和經理的決定,簿記期可以提前或推遲結束,並且可以隨時取消,因此,公司可以不完成私募配售。

The Company will announce the final number of Offer Shares placed and the final Offer Price in a stock exchange announcement expected to be published before the opening of trading on the Oslo Stock Exchange tomorrow, 16 November 2023.

公司將在明天,即2023年11月16日奧斯陸證券交易所開盤前發佈的證券交易所公告中宣佈發行的最終發行股份數量和最終要約價格。

The Private Placement will be directed towards Norwegian and international investors, in each case subject to applicable exemptions from relevant prospectus, filing or other registration requirements. The minimum application and allocation amount in the Private Placement will be the NOK equivalent of EUR 100,000, provided that the Company may, at its sole discretion, allocate an amount below EUR 100,000 to the extent applicable exemptions from relevant prospectus and registration requirements pursuant to applicable regulations, including Regulation (EU) 2017/1129 (the EU Prospectus Regulation) and ancillary regulations, are available.

私募將針對挪威和國際投資者,在每種情況下,均需遵守相關招股說明書、申報或其他註冊要求的適用豁免。私募中的最低申請和分配金額將等於100,000歐元的金額,前提是公司可以根據適用法規(歐盟)第2017/1129號法規(歐盟招股說明書條例)和輔助法規,在可獲得相關招股說明書和註冊要求的適用豁免範圍內,自行決定分配低於100,000歐元的金額。

The Private Placement may be divided into two tranches. Tranche 1 will consist of up to 131,603,374 Offer Shares ("Tranche 1" and the "Tranche 1 Offer Shares"). Tranche 2 will consist of up to the number of Offer Shares that, together with the Tranche 1 Offer Shares, is necessary in order to raise gross proceeds of up to NOK 35 million ("Tranche 2" and the "Tranche 2 Offer Shares"). Allocations of Offer Shares to investors are expected to be split between Tranche 1 and Tranche 2 on a pro rata basis. Completion of Tranche 2 will be subject to approval by the EGM. In the event the number of Offer Shares allocated is less than the number of Offer Shares available in Tranche 1, Tranche 2 will be cancelled.

私募可以分爲兩部分。第一批將包括最多131,603,374股發售股份(“第一批” 和 “第一批發售股份”)。第二批將包含最多可籌集3,500萬挪威克朗總收益所需的發售股份以及第一批發售股份(“第二批” 和 “第二批發售股份”)。預計向投資者分配的發售股份將在第一批和第二批之間按比例分配。第二階段的完成將有待臨時股東大會的批准。如果分配的發售股份數量少於第一批中可用的發售股份數量,則第二批將被取消。

Allocation of Offer Shares will be determined by the Board at its sole discretion, in consultation with the Manager, following the expiry of the bookbuilding period, however subject to approval by the EGM in respect of Tranche 2. Allocation will be based on criteria such as (but not limited to) pre-commitments, existing ownership in the Company, timeliness of the application, price leadership, relative order size, sector knowledge, investment history, perceived investor quality and investment horizon. The Board may, at its sole discretion, reject and/or reduce any applications, and there is no guarantee that any applicant will be allocated Offer Shares. Notification of allocation and payment instructions are expected to be issued to the applicants on or about 16 November 2023 through a notification to be issued by the Manager.

要約股份的分配將在簿記期滿後由董事會與經理協商後自行決定,但須經股東特別大會對第二部分的批准。分配將基於諸如(但不限於)預先承諾、公司現有所有權、申請的及時性、價格領先地位、相對訂單規模、行業知識、投資歷史、感知的投資者質量和投資前景等標準。董事會可自行決定拒絕和/或減少任何申請,並且不能保證任何申請人都會獲得發售股份。預計將在2023年11月16日左右通過經理發佈的通知向申請人發出分配通知和付款指示。

Completion of Tranche 1 is subject to approval by the Board. Completion of Tranche 2 is subject to (i) completion of Tranche 1, (ii) approval by the EGM and (iii) the Share Lending Agreement (as defined below) remaining in full force and effect. Further to this, completion of both Tranche 1 and Tranche 2 are subject to the Company resolving to consummate the Private Placement and allocate the Offer Shares. Completion of Tranche 1 will not be conditional upon or otherwise affected by the completion of Tranche 2, and the applicants' acquisition of Tranche 1 Offer Shares will remain final and binding and cannot be revoked, cancelled or terminated by the respective applicants if Tranche 2, for whatever reason, is not completed. Investors being allocated shares in the Private Placement undertake to vote in favour of Tranche 2 at the EGM.

第一階段的完成有待董事會的批准。第二批的完成前提是(i)第一部分的完成,(ii)股東特別大會的批准,(iii)股票貸款協議(定義見下文)仍然完全有效。除此之外,第一批和第二批的完成都取決於公司決心完成私募並分配要約股份。第一批的完成不以第二批的完成爲條件或以其他方式受到影響,申請人對第一批要約股份的收購將仍然是最終的,具有約束力,如果第二批由於任何原因未完成,則相應的申請人不能撤銷、取消或終止。獲得私募股權分配的投資者承諾在股東特別大會上對第二批投贊成票。

Both Tranche 1 and Tranche 2 will be settled with existing and unencumbered shares in the Company that are already listed on the Oslo Stock Exchange, pursuant to a share lending agreement expected to be entered into between the Company, the Manager and certain existing shareholders (the "Share Lending Agreement"). The share loan in Tranche 1 will be settled with new shares in the Company to be resolved issued by the Board pursuant to an authorisation by the Company's extraordinary general meeting held on 16 June 2023. The share loan in Tranche 2 will be settled with new shares in the Company expected to be issued following, and subject to, approval by the EGM. The new shares to be redelivered to the lenders under the Share Lending Agreement will, to the extent required, be delivered on a separate and non-tradable ISIN, pending publication by the Company of a listing prospectus approved by the Norwegian Financial Supervisory Authority.

根據公司、經理和某些現有股東預計將簽訂的股票貸款協議(“股票貸款協議”),第一批和第二批將以已經在奧斯陸證券交易所上市的公司現有和未抵押股份進行結算。根據公司於2023年6月16日舉行的股東特別大會的授權,第一批股份貸款將由董事會發行的新股結算。第二批的股票貸款將由公司的新股結算,預計將在股東特別大會批准後發行。在公司公佈挪威金融監管局批准的上市招股說明書之前,根據股票貸款協議重新交付給貸款人的新股將在需要的範圍內以單獨且不可交易的ISIN交割。

Settlement of the Tranche 1 Offer Shares is expected to take place on a delivery versus payment basis on or about 20 November 2023. Settlement of the Tranche 2 Offer Shares is expected to take place on a delivery versus payment basis on or about 12 December 2023, subject to approval by the EGM.
The Company reserves the right, at any time and for any reason, to cancel, and/or modify the terms of, the Private Placement prior to delivery of the Tranche 1 Offer Shares. Furthermore, Tranche 2 will be cancelled if the number of Offer Shares allocated is less than the number of Offer Shares available in Tranche 1 and if the conditions for completion of Tranche 2 are not satisfied. Neither the Company nor the Manager will be liable for any losses incurred by applicants if the Private Placement is cancelled, irrespective of the reason for such cancellation.

第一批發售股份的結算預計將在2023年11月20日左右以交割與付款的方式進行。第二批要約股份的結算預計將於2023年12月12日左右以交割與付款的方式進行,但須經臨時股東特別大會批准。
公司保留在交付第一批要約股份之前隨時以任何理由取消和/或修改私募條款的權利。此外,如果分配的要約股份數量少於第一批可用的要約股份數量,並且第二批的完成條件未得到滿足,則第二批將被取消。如果私募配售被取消,公司和經理均不對申請人造成的任何損失負責,無論取消的原因如何。

The Board has considered the Private Placement in light of the equal treatment obligations under the Norwegian Public Limited Companies Act, the Norwegian Securities Trading Act, the rules on equal treatment under Oslo Rule Book II for companies listed on the Oslo Stock Exchange and the Oslo Stock Exchange's Guidelines on the rule of equal treatment, and deems that the proposed Private Placement is in compliance with these requirements. The Board holds the view that it will be in the common interest of the Company and its shareholders to raise equity through a private placement, in view of the current market conditions and the funding alternatives currently available to the Company. A private placement enables the Company to raise capital in an efficient manner, and the Private Placement is structured to ensure that a market-based subscription price is achieved. The Company is of the view that the discount in a rights issue would have to be quite significant, and that a rights issue would need to be guaranteed by a consortium of underwriters, which would entail an added cost for the Company. By structuring the equity raise as a private placement, the Company is expected to be in a position to raise capital at a better share price, at a lower cost and with significantly lower risk than in a rights issue.

董事會根據《挪威公共有限公司法》、《挪威證券交易法》、奧斯陸證券交易所上市公司的奧斯陸規則第二卷規定的平等待遇規則以及奧斯陸證券交易所關於平等待遇規則的指導方針對私募進行了審議,並認爲擬議的私募符合這些要求。董事會認爲,鑑於當前的市場狀況和公司目前可用的融資選擇,通過私募籌集股權符合公司及其股東的共同利益。私募使公司能夠以有效的方式籌集資金,私募的結構旨在確保實現基於市場的認購價格。該公司認爲,供股的折扣必須相當大,供股需要由承銷商財團擔保,這將增加公司的成本。通過將股權籌集結構化爲私募發行,預計公司將能夠以更優惠的股價、更低的成本和風險遠低於供股籌集資金。

The Company may, subject to completion of the Private Placement, approval from the EGM and certain other conditions, consider to carry out a subsequent repair offering of new shares at the Offer Price directed towards existing shareholders in the Company as of 15 November 2023 (as registered in the VPS on 17 November 2023), who were not allocated Offer Shares in the Private Placement and who are not resident in a jurisdiction where such offering would be unlawful or, for jurisdictions other than Norway, would require any prospectus, filing, registration or similar action.

在私募配售完成、臨時股東大會批准和某些其他條件的前提下,公司可以考慮隨後按要約價向截至2023年11月15日的公司現有股東(2023年11月17日在VPS中註冊)進行新股的修復發行,這些股東未在私募中獲得要約股份,也不居住在此類發行不合法的司法管轄區,或者對於挪威以外的司法管轄區而言,這些股東會被分配發行股份需要任何招股說明書、備案、註冊或類似文件行動。

This information in this stock exchange announcement is considered to be inside information pursuant to the EU Market Abuse Regulation and is published in accordance with section 5-12 the Norwegian Securities Trading Act.

根據《歐盟市場濫用條例》,本證券交易所公告中的這些信息被視爲內幕信息,並根據《挪威證券交易法》第5-12條發佈。

This stock exchange announcement was published by Marianne Bøe, Head of Investor Relations on 15 November 2023 at 16:30 CET on behalf of the Company.

本證券交易所公告由投資者關係主管瑪麗安·博伊於歐洲中部時間2023年11月15日 16:30 代表公司發佈。

Contact person:

聯繫人:

Marianne Bøe, Head of Investor Relations
E-mail: marianne.boe@idexbiometrics.com
Tel: +47 91 80 01 86

瑪麗安·博伊,投資者關係主管
電子郵件: marianne.boe@idexbiometrics.com
電話:+47 91 80 01 86

About IDEX Biometrics:

關於 IDEX 生物識別技術:

IDEX Biometrics ASA (OSE: IDEX) is a global technology leader in fingerprint biometrics, offering authentication solutions across payments, access control, and digital identity. Our solutions bring convenience, security, peace of mind and seamless user experiences to the world. Built on patented and proprietary sensor technologies, integrated circuit designs, and software, our biometric solutions target card-based applications for payments and digital authentication. As an industry-enabler we partner with leading card manufacturers and technology companies to bring our solutions to market. .

IDEX Biometrics ASA(OSE:IDEX)是指紋生物識別領域的全球技術領導者,提供跨支付、訪問控制和數字身份的身份驗證解決方案。我們的解決方案爲世界帶來便利、安全、安心和無縫的用戶體驗。我們的生物識別解決方案建立在專利和專有傳感器技術、集成電路設計和軟件的基礎上,適用於基於卡的支付和數字身份驗證應用。作爲行業推動者,我們與領先的卡製造商和技術公司合作,將我們的解決方案推向市場。

For more information, visit

欲了解更多信息,請訪問

IMPORTANT INFORMATION:

重要信息:

This announcement is not and does not form a part of any offer to sell, or a solicitation of an offer to purchase any securities. The distribution of this announcement and other information may be restricted by law in certain jurisdictions. Copies of this announcement are not being made and may not be distributed or sent into any jurisdiction in which such distribution would be unlawful or would require registration or other measures. Persons into whose possession this announcement or such other information should come are required to inform themselves about and to observe any such restrictions.

本公告不是也不構成任何出售要約或購買任何證券的要約的一部分。在某些司法管轄區,本公告和其他信息的發佈可能會受到法律的限制。本公告的副本沒有製作,也不得分發或發送到任何此類分發不合法或需要註冊或其他措施的司法管轄區。本應持有本公告或此類其他信息的人必須告知自己並遵守任何此類限制。

This announcement is not an offer of securities for sale in the United States. The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and accordingly may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and in accordance with applicable U.S. state securities laws. Any public offering of securities to be made in the United States would be made by means of a prospectus to be obtained from the Company that would contain detailed information about the Company and management, as well as financial statements; however, the Company does not intend to register any part of the offering or their securities in the United States or to conduct a public offering of securities in the United States. Any sale in the United States of the securities mentioned in this announcement will be made to "qualified institutional buyers" as defined in Rule 144A under the Securities Act or, with respect to institutions or to any existing director or executive officer of the Company only, "accredited investors" as defined in Regulation D under the Securities Act.

本公告不是要約在美國出售證券。本公告中提及的證券過去和將來都不會根據經修訂的1933年《美國證券法》(“證券法”)進行註冊,因此,如果沒有註冊或適用的《證券法》註冊要求豁免,也沒有適用的美國州證券法,則不得在美國發行或出售。在美國進行的任何證券公開發行都將通過向公司索取的招股說明書進行,該招股說明書將包含有關公司和管理層的詳細信息以及財務報表;但是,公司不打算在美國註冊發行的任何部分或其證券,也不打算在美國公開發行證券。在美國出售本公告中提及的證券將向《證券法》第144A條所定義的 “合格機構買家”,或者,就機構或公司任何現有董事或執行官而言,僅向《證券法》D條所定義的 “合格投資者” 進行。

In any EEA Member State, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Regulation, i.e., only to investors who can receive the offer without an approved prospectus in such EEA Member State. The expression "Prospectus Regulation" means Regulation 2017/1129 as amended together with any applicable implementing measures in any Member State. This communication is only being distributed to and is only directed at persons in the United Kingdom that are (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order") or (ii) high net worth entities, and other persons to whom this announcement may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "relevant persons"). This communication must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this communication relates is available only for relevant persons and will be engaged in only with relevant persons. Persons distributing this communication must satisfy themselves that it is lawful to do so.

在任何歐洲經濟區成員國,本通信僅發給並僅針對《招股說明書條例》所指的該成員國的合格投資者,也就是說,僅發送給在該歐洲經濟區成員國無需批准招股說明書即可獲得報價的投資者。“招股說明書條例” 一詞是指經修訂的第2017/1129號法規以及任何成員國的任何適用的實施措施。本來文僅分發給且僅針對英國境內的以下人員:(i)屬於經修訂的2005年《金融服務和市場法(金融促進)令》(以下簡稱 “法令”)第19(5)條的投資專業人士,或(ii)高淨值實體,以及可以合法向其發送本公告的其他人,屬於該命令第49(2)(a)至(d)條的範圍(全部這些人統稱爲 “相關人員”)。非相關人員不得根據本來文采取行動或依賴本來文。本來文所涉及的任何投資或投資活動僅適用於相關人員,並且只能與相關人員一起參與。分發這份來文的人必須確信這樣做是合法的。

Matters discussed in this announcement may constitute forward-looking statements, including in respect of the Company's intention to conduct and consummate the Private Placement and the manner in which the Company intends to utilize the proceeds therefrom. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe", "expect", "anticipate", "strategy", "intends", "estimate", "will", "may", "continue", "should" and similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believe that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond its control.

本公告中討論的事項可能構成前瞻性陳述,包括與公司進行和完成私募配售的意圖以及公司打算如何使用私募所得收益有關的前瞻性陳述。前瞻性陳述是非歷史事實的陳述,可以用 “相信”、“期望”、“預期”、“策略”、“打算”、“估計”、“將”、“可能”、“繼續”、“應該” 和類似的表達方式來識別。本新聞稿中的前瞻性陳述基於各種假設,而其中許多假設又基於進一步的假設。儘管公司認爲這些假設在做出時是合理的,但這些假設本質上會受到重大的已知和未知風險、不確定性、突發事件和其他重要因素的影響,這些因素難以或無法預測且超出其控制範圍。

Actual events may differ significantly from any anticipated development due to a number of factors, including without limitation, changes in public sector investment levels, changes in the general economic, political and market conditions in the markets in which the Company operate, the Company's ability to attract, retain and motivate qualified personnel, changes in the Company's ability to engage in commercially acceptable acquisitions and strategic investments, and changes in laws and regulation and the potential impact of legal proceedings and actions. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not provide any guarantees that the assumptions underlying the forward-looking statements in this announcement are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this announcement or any obligation to update or revise the statements in this announcement to reflect subsequent events. You should not place undue reliance on the forward-looking statements in this document. The information, opinions and forward-looking statements contained in this announcement speak only as at its date, and are subject to change without notice. The Company does not undertake any obligation to review, update, confirm, or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this announcement.

由於多種因素,包括但不限於公共部門投資水平的變化、公司運營所在市場的總體經濟、政治和市場條件的變化、公司吸引、留住和激勵合格人員的能力、公司進行商業上可接受的收購和戰略投資的能力的變化,以及法律和法規的變化以及法律訴訟和訴訟的潛在影響,實際事件可能與任何預期的事態發展大相徑庭。此類風險、不確定性、突發事件和其他重要因素可能導致實際事件與此類前瞻性陳述在本新聞稿中表達或暗示的預期存在重大差異。公司不保證本公告中前瞻性陳述所依據的假設沒有錯誤,也不對本公告中表達的觀點的未來準確性承擔任何責任,也不承擔任何更新或修改本公告中陳述以反映後續事件的義務。您不應過分依賴本文檔中的前瞻性陳述。本公告中包含的信息、觀點和前瞻性陳述僅代表其發佈日期,如有更改,恕不另行通知。公司沒有義務審查、更新、確認或公開發布對任何前瞻性陳述的任何修訂,以反映與本公告內容有關的事件或出現的情況。

This announcement is made by, and is the responsibility of, the Company. Neither the Manager nor any of its affiliates makes any representation as to the accuracy or completeness of this announcement and none of them accepts any responsibility for the contents of this announcement or any matters referred to herein.

本公告由公司發佈並由公司負責。經理及其任何關聯公司均不對本公告的準確性或完整性作任何陳述,他們均不對本公告的內容或本公告中提及的任何事項承擔任何責任。

This announcement is for information purposes only and is not to be relied upon in substitution for the exercise of independent judgment. It is not intended as investment advice and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of an offer to buy any securities or a recommendation to buy or sell any securities in the Company. Neither the Manager nor any of its affiliates accepts any liability arising from the use of this announcement.

本公告僅供參考,不能用來代替行使獨立判斷。它不用作投資建議,在任何情況下都不得將其用作或被視爲出售要約,也不得被視爲購買任何證券的要約或買入或賣出公司任何證券的建議。經理及其任何關聯公司均不接受因使用本公告而產生的任何責任。

About this notice:

關於本通知:

This notice was published by Erling Svela, Vice president of finance, on 15 November 2023 at 16:30 CET on behalf of IDEX Biometrics ASA.

本通知由財務副總裁埃爾林·斯維拉於歐洲中部時間2023年11月15日 16:30 代表IDEX Biometrics ASA發佈。


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論